Craig D. Shimasaki

Moleculera Labs, Inc. provides clinical testing services for children and families suspected of suffering from Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS)/Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), which are treatable neurologic conditions that may be associated with motor tics, obsessive compulsive disorders, and sometimes Autism Spectrum Disorders. It offers its services to the physician as an aid in their diagnosis of PANDAS/PANS/Childhood Acute Neuropsychiatric Symptoms in parts of the United States. The company was founded by Madeleine Cunningham and Craig Shimasaki in 2011 and is headquartered in Oklahoma City, OK.

Moleculera Labs, Inc. provides clinical testing services for children and families suspected of suffering from Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS)/Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), which are treatable neurologic conditions that may be associated with motor tics, obsessive compulsive disorders, and sometimes Autism Spectrum Disorders. It offers its services to the physician as an aid in their diagnosis of PANDAS/PANS/Childhood Acute Neuropsychiatric Symptoms in parts of the United States. The company was founded by Madeleine Cunningham and Craig Shimasaki in 2011 and is headquartered in Oklahoma City, OK.

Moleculera Labs, Inc. provides clinical testing services for children and families suspected of suffering from Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS)/Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), which are treatable neurologic conditions that may be associated with motor tics, obsessive compulsive disorders, and sometimes Autism Spectrum Disorders. It offers its services to the physician as an aid in their diagnosis of PANDAS/PANS/Childhood Acute Neuropsychiatric Symptoms in parts of the United States. The company was founded by Madeleine Cunningham and Craig Shimasaki in 2011 and is headquartered in Oklahoma City, OK.

Moleculera Labs, Inc. provides clinical testing services for children and families suspected of suffering from Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS)/Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), which are treatable neurologic conditions that may be associated with motor tics, obsessive compulsive disorders, and sometimes Autism Spectrum Disorders. It offers its services to the physician as an aid in their diagnosis of PANDAS/PANS/Childhood Acute Neuropsychiatric Symptoms in parts of the United States. The company was founded by Madeleine Cunningham and Craig Shimasaki in 2011 and is headquartered in Oklahoma City, OK.

Moleculera Labs, Inc. provides clinical testing services for children and families suspected of suffering from Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS)/Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), which are treatable neurologic conditions that may be associated with motor tics, obsessive compulsive disorders, and sometimes Autism Spectrum Disorders. It offers its services to the physician as an aid in their diagnosis of PANDAS/PANS/Childhood Acute Neuropsychiatric Symptoms in parts of the United States. The company was founded by Madeleine Cunningham and Craig Shimasaki in 2011 and is headquartered in Oklahoma City, OK.

Moleculera Labs, Inc. provides clinical testing services for children and families suspected of suffering from Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS)/Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), which are treatable neurologic conditions that may be associated with motor tics, obsessive compulsive disorders, and sometimes Autism Spectrum Disorders. It offers its services to the physician as an aid in their diagnosis of PANDAS/PANS/Childhood Acute Neuropsychiatric Symptoms in parts of the United States. The company was founded by Madeleine Cunningham and Craig Shimasaki in 2011 and is headquartered in Oklahoma City, OK.

Moleculera Labs, Inc. provides clinical testing services for children and families suspected of suffering from Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS)/Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), which are treatable neurologic conditions that may be associated with motor tics, obsessive compulsive disorders, and sometimes Autism Spectrum Disorders. It offers its services to the physician as an aid in their diagnosis of PANDAS/PANS/Childhood Acute Neuropsychiatric Symptoms in parts of the United States. The company was founded by Madeleine Cunningham and Craig Shimasaki in 2011 and is headquartered in Oklahoma City, OK.